The Agency for Medicinal Products and Medical Devices (HALMED) would like to inform about the recall of the batch 140802 of Ramipril H Farmal 2.5 mg/12.5 mg tablets of the marketing authorisation holder Farmal d.d. due to a discovered quality defect.
The recall is being carried out to the pharmacy level or delivery site to patients. Patients already taking this batch of the medicine may continue to use it, as it is concluded that it has no impact on the safe use of this medicine and the recall is being ...
On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.
myHealthbox™ provides a platform to access official Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) documents on healthcare products including: human, animal and plants medications; drugs; herbal, homoeopathic and natural remedies; prescription and over-the-counter medicines; beauty products and cosmetics; supplements and medical devices.